#1 Clinical Trials Search in Europe

Inupadenant Hydrochloride

This article discusses clinical trials investigating the use of Inupadenant Hydrochloride, a novel drug, in treating advanced solid tumors and non-small cell lung cancer (NSCLC). The trials aim to evaluate the safety, efficacy, and optimal dosing of Inupadenant Hydrochloride when used alone or in combination with other cancer treatments.

Table of Contents

What is Inupadenant Hydrochloride?

Inupadenant Hydrochloride, also known as EOS100850, is an investigational drug being developed for the treatment of advanced solid tumors[1]. It is a chemical compound that belongs to a class of drugs called immunotherapies, which work by enhancing the body’s immune system to fight cancer.

How It Works

While the exact mechanism of action is not fully described in the provided clinical trial information, inupadenant hydrochloride is likely designed to target specific pathways in the immune system. It may work by blocking certain proteins or receptors that cancer cells use to evade the immune system, thereby allowing the body’s natural defenses to recognize and attack the tumor cells more effectively.

Conditions Treated

Inupadenant hydrochloride is being studied for the treatment of various advanced solid tumors[1]. Specifically, it is being investigated for:

  • Non-small cell lung cancer (NSCLC): Particularly in patients with metastatic or locally advanced, unresectable Stage III nonsquamous NSCLC that has relapsed or progressed[2].
  • Head and neck squamous cell carcinoma (HNSCC): In patients with first-line metastatic HNSCC[1].
  • Cutaneous melanoma: Specifically in patients with anti-PD-(L)1 resistant metastatic cutaneous melanoma[1].

Clinical Trials

Inupadenant hydrochloride is currently being evaluated in several clinical trials:

1. A Phase I/II study (2024-512227-36-00) is investigating the drug in combination with other therapies for advanced solid tumors[1]. This study aims to:

  • Determine the safety and tolerability of inupadenant in combination with other treatments
  • Identify the recommended Phase 2 dose (RP2D)
  • Assess the anti-tumor activity in various cancer types

2. A Phase II study (2024-515393-27-00) is evaluating inupadenant in combination with carboplatin and pemetrexed for nonsquamous non-small cell lung cancer (NSCLC) patients who have progressed on immunotherapy[2]. This study aims to:

  • Evaluate the efficacy and safety of the combination treatment
  • Assess progression-free survival (PFS) as the primary endpoint
  • Measure overall response rate (ORR), duration of response (DoR), and overall survival (OS) as secondary endpoints

Potential Benefits

While the full results of these clinical trials are not yet available, inupadenant hydrochloride shows promise in treating advanced solid tumors, particularly in patients who have progressed on previous treatments. Potential benefits being investigated include:

  • Improved anti-tumor activity when combined with other therapies
  • Potential efficacy in patients who have become resistant to other immunotherapies
  • Possible extension of progression-free survival and overall survival

Side Effects and Safety

As with all investigational drugs, the full safety profile of inupadenant hydrochloride is still being determined through clinical trials. The studies are carefully monitoring for adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)[1][2]. Patients considering participation in clinical trials should discuss potential risks and side effects with their healthcare provider.

Administration

Inupadenant hydrochloride is being studied in capsule form for oral administration[1][2]. The optimal dosing schedule and duration of treatment are still being determined through the ongoing clinical trials.

Future Research

As inupadenant hydrochloride continues to be studied, future research may focus on:

  • Identifying biomarkers to predict which patients are most likely to benefit from the treatment
  • Exploring additional combination therapies to enhance efficacy
  • Investigating its potential in other types of solid tumors
  • Long-term follow-up to assess durability of response and overall survival benefits

Patients interested in learning more about inupadenant hydrochloride or participating in clinical trials should consult with their oncologist to determine if they may be eligible for ongoing studies.

Aspect Details
Drug Name Inupadenant Hydrochloride
Cancer Types Studied Advanced solid tumors, metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)
Trial Phases Phase I/II and Phase II
Administration Oral capsules
Combination Therapies Carboplatin, pemetrexed, dostarlimab, pembrolizumab
Primary Objectives Safety, tolerability, efficacy, optimal dosing
Key Endpoints Progression-free survival (PFS), overall response rate (ORR), adverse events
Eligibility Adults with advanced solid tumors or specific lung cancers, meeting health criteria

FAQ

  • What is Inupadenant Hydrochloride? Inupadenant Hydrochloride is an investigational drug being studied for the treatment of advanced solid tumors and non-small cell lung cancer. It is being evaluated both as a single agent and in combination with other cancer treatments.
  • What types of cancer are being studied in these trials? The clinical trials are focusing on advanced solid tumors, metastatic non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC).
  • How is Inupadenant Hydrochloride administered? Inupadenant Hydrochloride is administered orally in capsule form.
  • What are the main goals of these clinical trials? The main goals are to evaluate the safety and efficacy of Inupadenant Hydrochloride, determine the optimal dosing, and assess its potential benefits when combined with other cancer treatments like chemotherapy and immunotherapy.
  • Who is eligible to participate in these trials? Eligibility varies by trial, but generally includes adults with advanced solid tumors or specific types of lung cancer who have progressed on previous treatments. Participants must meet certain health criteria and have measurable disease.

Ongoing Clinical Trials on Inupadenant Hydrochloride

  • Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy Spain

  • Study of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy Spain

Glossary

  • NSCLC: Non-small cell lung cancer, a type of lung cancer that is one of the main focuses of these clinical trials.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • PD-L1: Programmed death-ligand 1, a protein that plays a role in suppressing the immune response. Its expression status is important in some of these trials.
  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
  • Chemotherapy: A type of cancer treatment that uses drugs to destroy cancer cells.
  • Carboplatin: A chemotherapy drug used in some of the trials in combination with Inupadenant Hydrochloride.
  • Pemetrexed: Another chemotherapy drug used in combination with Inupadenant Hydrochloride in some trials.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.

References

  1. http://clinicaltrials.eu/trial/study-of-eos884448-dostarlimab-and-inupadenant-for-patients-with-advanced-solid-tumors/
  2. http://clinicaltrials.eu/trial/study-on-inupadenant-carboplatin-and-pemetrexed-for-adults-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy/